University of Alabama at Birmingham: Ovarian Neoplasms trials

The registry lists 17 Ovarian Neoplasms studies with University of Alabama at Birmingham as lead sponsor. 4 are open to participants now and 1 have results posted.

Phase 1 7Phase 2 2No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE StudyRecruitingNCT07671937Not applicable
• Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/PembroRecruitingNCT05952453Phase 2
• Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT04606914Phase 2
• The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in TamponsRecruitingNCT03538665
• Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor HealthCompletedNCT04000880Not applicableResults posted
• Interventions to Decrease Financial ToxicityCompletedNCT05939440Not applicable
• Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian CancerWithdrawnNCT04542603Phase 1
• Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian CancerWithdrawnNCT04149145Phase 1
• CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer PatientsTerminatedNCT03944902Phase 1
• Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)CompletedNCT02374827Not applicable
• Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian CancerCompletedNCT02195973Phase 1
• A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic CancersCompletedNCT00964756Phase 1
• The Effect of TRA-8 on Ovarian Cancer TissueCompletedNCT00711932
• Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer PatientsCompletedNCT00562003Phase 1
• Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian CancerTerminatedNCT00317434Phase 1
• Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic OophorectomyWithdrawnNCT00084370Not applicable
• CA-125 in Screening Patients at High Risk for Ovarian CancerWithdrawnNCT00080639